8月21日，三生制药盘中上涨5.58%，报17.47港元，成交额1.95亿港元。
消息面上，公司于8月20日发布中期业绩，上半年实现营业收入45.26亿元，同比增长3.9%；归母净利润11.47亿元，同比下降15.6%，但经调整经营性归母净利润14.4亿元，同比增长26.5%。海外产品销售同比增长43%，核心品种获全球23个国家上市许可。此外，国家药监局于8月20日正式批准公司旗下非甾体抗炎药物的上市申请，进一步增强公司在抗炎镇痛领域的竞争力。董事长娄竞此前曾增持公司股份，叠加6月公司连续回购，彰显管理层信心。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.